Evidence map›Paper›PMID 37218811›Full record

ReviewJournal of xenobiotics2023

Systematic Review of Safety of Selective Androgen Receptor Modulators in Healthy Adults: Implications for Recreational Users.

Jonathan D Vignali, Kevin C Pak, Holly R Beverley, Jesse P DeLuca, John W Downs, Adrian T Kress, Brett W Sadowski, Daniel J Selig

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of xenobiotics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Amino-Acid-Derived Androgen Receptor Modulators.ACS medicinal chemistry letters · 2026
    Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Jonathan D VignaliBehavioral Biology Branch, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.
Kevin C PakDepartment of Gastroenterology, Naval Medical Center San Diego, San Diego, CA 92134, USA.
Holly R BeverleyGorgas Memorial Library, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.ORCID 0000-0001-7930-9542
Jesse P DeLucaClinical Pharmacology Fellowship, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.
John W DownsDepartment of Toxicology, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.
Adrian T KressClinical Pharmacology Fellowship, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.
Brett W SadowskiDepartment of Gastroenterology, Naval Medical Center San Diego, San Diego, CA 92134, USA.
Daniel J SeligClinical Pharmacology Fellowship, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.ORCID 0000-0002-6107-5984
Walter Reed Army Institute of Research · USNaval Medical Center San Diego · USUniformed Services University of the Health Sciences · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Selective Androgen Receptor Modulators (SARMs) are not FDA approved, and obtaining SARMs for personal use is illegal. Nevertheless, SARM use is increasingly popular amongst recreational athletes. Recent case reports of drug-induced liver injury (DILI) and tendon rupture raise serious concerns for the safety of recreational SARM users. On 10 November 2022 PubMed, Scopus, Web of Science, and ClinicalTrials.gov were searched for studies that reported safety data of SARMs. A multi-tiered screening approach was utilized, and any study or case report of generally healthy individuals exposed to any SARM was included. Thirty-three studies were included in the review with 15 case reports or case series and 18 clinical trials (total patients N = 2136 patients, exposed to SARM N = 1447). There were case reports of drug-induced liver injury (DILI) (N = 15), Achilles tendon rupture (N = 1), rhabdomyolysis (N = 1), and mild reversible liver enzyme elevation (N = 1). Elevated alanine aminotransferase (ALT) was commonly reported in clinical trials in patients exposed to SARM (mean 7.1% across trials). Two individuals exposed to GSK2881078 in a clinical trial were reported to have rhabdomyolysis. Recreational SARM use should be strongly discouraged, and the risks of DILI, rhabdomyolysis, and tendon rupture should be emphasized. However, despite warnings, if a patient refuses to discontinue SARM use, ALT monitoring or dose reduction may improve early detection and prevention of DILI.

Indexed as

athletedrug-induced liver injurydrug safetyrecreationselective androgen receptor modulatortendon rupture

Identifiers

PMID37218811
PMCPMC10204391
OpenAlexW4377564699

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.